Autopsy report · NCT01025713

A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)

“Development program terminated.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Gilead Sciences

Sponsor type

Industry

Conditions

Cystic Fibrosis; Mucociliary Clearance

Interventions

GS-9411; Placebo

Participants

0

Sites

1

Countries

Australia

Trials that died the same way

• GALLANT 22 Tesaglitazar vs. Placebo
  “The development program has been terminated” (94% match in meaning)
• Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM Patients
  “Program terminated” (80% match in meaning)
• A Randomized Double Blind, Placebo Controlled Trial With AMG 108 in Patients With Type 2 Diabetes Mellitus
  “Program Development discontinued” (70% match in meaning)
• Physician's Comfort Level and Satisfaction Study With The e2TM Collector Compared to the Spatula/CytoBrush Technique
  “Terminated for lack of resources to complete.” (67% match in meaning)
• Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
  “Program terminated due to lack of meaningful efficacy signal.” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.